Keytruda (Pembrolizumab) – Uses, Mechanism & Side Effects
Keytruda (pembrolizumab) is a cancer medication and immune checkpoint inhibitor that helps the immune system detect and destroy tumor cells.
Things worth knowing about "Keytruda"
Keytruda (pembrolizumab) is a cancer medication and immune checkpoint inhibitor that helps the immune system detect and destroy tumor cells.
What is Keytruda?
Keytruda is the brand name for pembrolizumab, a monoclonal antibody classified as an immune checkpoint inhibitor. It is manufactured by MSD (Merck Sharp & Dohme) and is widely used in oncology. Keytruda has received approval from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) for a broad range of cancer indications, making it one of the most widely approved cancer immunotherapies in the world.
Mechanism of Action
The immune system uses checkpoints to prevent itself from attacking healthy tissue. Cancer cells exploit this mechanism by expressing a protein called PD-L1 (Programmed Death-Ligand 1) on their surface, which essentially makes them invisible to immune cells.
Pembrolizumab works by blocking the PD-1 (Programmed Cell Death Protein 1) receptor found on T-lymphocytes (immune cells). By blocking this receptor, the suppressive signal is removed, allowing T-cells to recognize and attack tumor cells once again.
Approved Indications
Keytruda is approved for a wide range of cancers, including:
- Non-small cell lung cancer (NSCLC) – as first- or second-line therapy
- Melanoma – in advanced or metastatic stages
- Triple-negative breast cancer
- Urothelial carcinoma (bladder cancer)
- Head and neck squamous cell carcinoma (HNSCC)
- Colorectal cancer with high microsatellite instability (MSI-H)
- Cervical cancer
- Endometrial carcinoma
- Gastric and esophageal cancer
- Hepatocellular carcinoma (liver cancer)
- Other tumor types in combination with additional therapies
Dosage and Administration
Keytruda is administered as an intravenous (IV) infusion, typically over 30 minutes. The standard dosing regimens are:
- 200 mg every 3 weeks or
- 400 mg every 6 weeks
The exact dosage and treatment plan are determined individually by the treating oncologist based on the type and stage of cancer and the overall health of the patient. Treatment may continue for several months to years.
Side Effects
Because Keytruda activates the immune system, it can cause immune-related adverse events (irAEs), which can potentially affect almost any organ. Common side effects include:
- Fatigue and weakness
- Skin rash and itching
- Diarrhea and colitis (intestinal inflammation)
- Pneumonitis (lung inflammation)
- Thyroid disorders (hypothyroidism or hyperthyroidism)
- Hepatitis (liver inflammation)
- Nephritis (kidney inflammation)
- Hormonal disorders (endocrinopathies)
Severe immune-related side effects require prompt medical management, usually with corticosteroids (e.g., prednisone) to suppress the excessive immune response. In some cases, treatment with Keytruda must be paused or permanently discontinued.
Biomarkers and Patient Selection
Not all patients respond equally well to Keytruda. A key predictive biomarker is PD-L1 expression in the tumor, which is measured from a tissue sample (biopsy). Higher PD-L1 expression generally correlates with a better response to treatment. Additional biomarkers such as tumor mutational burden (TMB) and microsatellite instability (MSI) can also guide patient selection.
Combination Therapies
Keytruda is frequently used in combination with other cancer treatments, including:
- Chemotherapy (e.g., platinum-based regimens)
- Other targeted therapies (e.g., tyrosine kinase inhibitors)
- Antiangiogenic agents (e.g., bevacizumab, lenvatinib)
These combination approaches can enhance treatment efficacy but may also increase the risk of side effects, requiring close monitoring by the medical team.
References
- European Medicines Agency (EMA): Keytruda (pembrolizumab) – Product information and approval status. Available at: https://www.ema.europa.eu
- Brahmer, J. R. et al. (2022): Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. Journal of Clinical Oncology, 40(12), 1370–1399.
- Robert, C. et al. (2021): Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006). New England Journal of Medicine, 372(26), 2521–2532.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: Keytruda